CHI3L1 and colonic neoplasm: The results showed that the sensitivity to cetuximab was significantly improved both in CHI3L1 overexpressed and exogenous CHI3L1 added colon cancer cells, indicating that high levels of CHI3L1 could increase the sensitivity of cells to cetuximab, which was consistent with the results of Tarpgaard's study.